Biogen Q4 Beat Sparks $66M Zurzuvae Sales, Boosting Supernus Partnership
Biogen’s Q4 adjusted EPS of $1.99 topped estimates as fourth-quarter revenues declined 7% to $2.28 billion, driven by legacy MS drug erosion. Postpartum depression drug Zurzuvae generated $66 million in Q4 sales, up 19% sequentially, with Supernus entitled to 50% of U.S. profits and ex-U.S. royalties after EU approval.
1. Q4 Performance and Zurzuvae Uptick
Biogen delivered adjusted EPS of $1.99 in Q4, beating consensus, despite a 7% year-over-year revenue decline to $2.28 billion. New therapies offset MS portfolio pressure, with Zurzuvae sales rising 19% sequentially to $66 million.
2. Supernus Partnership and Revenue Implications
Under the U.S. co-commercialization agreement, Supernus shares 50% of Zurzuvae’s U.S. profits and receives royalties on ex-U.S. sales. The drug’s EU approval last September extends Supernus’s royalty stream as commercialization expands.